TROBIX BIO

2Likes

664Views

2020Mar 9

Trobix Bio is developing a novel and game changing approach to treating AMR, addressing one of the most pressing concerns in the field – the fact that bacteria always develop resistance to any drug. Thus, aiming to kill bacteria is simply not enough. The innovation behind the company uses non-replicating phage-based particles alongside a CRISPR-based Trojan horse technology, to actively sensitize, for the first time, antibiotic-resistant bacteria to antibiotics, circumventing bacteria from developing resistance to derived products. Trobix Bio lead product, TBX101, developed as an orally available pill, targets the large population carrying resistant bacteria in their gut that spread deadly infections in medical centers. Specific targeting and sensitizing of gut resistant bacteria is an innovative approach to microbiome management, offering for the first time a preventative treatment that holds the potential to dramatically reduce hospital morbidity and mortality caused by such pathogens. Trobix Bio plans to leverage its platform technology to develop a portfolio of high-quality anti-bacterial products across multiple business sectors. Learn more about Trobix Bio: https://www.trobixbio.com/